The Mitsubishi Tanabe Pharma Group engages Healthcare Professionals (HCPs) and Healthcare Organisations (HCOs) across Europe.

In accordance with the EFPIA Code of Transfers of Value from Pharmaceutical Companies 2019, details of Transfers of Value made to HCPs and HCOs in Europe by the Mitsubishi Tanabe Pharma Group can be found below. 

The methodology applied in preparing and collating this data is available here in English*, French* and German*.

If you are a Healthcare Professional and have any questions regarding the figures disclosed, please contact: 
Finance@mt-pharma-eu.com.

2021 Transfers of Value

Austria
Research & Development EUR 40,778.84
Non-Research & Development EUR 48,577.80
Belgium
Research & Development EUR 27,995.79
Non-Research & Development EUR 0.00
Bulgaria
Research & Development EUR 0.00
Non-Research & Development EUR 0.00
Croatia
Research & Development EUR 0.00
Non-Research & Development EUR 0.00
Cyprus
Research & Development EUR 0.00
Non-Research & Development EUR 0.00
Czech Republic
Research & Development CZK 519,851.60
Non-Research & Development CZK 0.00
Denmark
Research & Development EUR 0.00
Non-Research & Development EUR 0.00
Estonia
Research & Development EUR 0.00
Non-Research & Development EUR 0.00
Finland
Research & Development EUR 0.00
Non-Research & Development EUR 0.00
France
Research & Development EUR 856,845.53
Non-Research & Development EUR 0.00
Germany
Research & Development EUR 453,553.98
Non-Research & Development EUR 102,665.00
Greece
Research & Development EUR 0.00
Non-Research & Development EUR 0.00
Hungary
Research & Development HUF 4,006,692.08
Non-Research & Development HUF 0.00
Ireland
Research & Development EUR 0.00
Non-Research & Development EUR 0.00
Italy
Research & Development EUR 219,476.61
Non-Research & Development EUR 0.00
Latvia
Research & Development EUR 0.00
Non-Research & Development EUR 0.00
Lithuania
Research & Development EUR 0.00
Non-Research & Development EUR 0.00
Malta
Research & Development EUR 0.00
Non-Research & Development EUR 0.00
The Netherlands
Research & Development EUR 6,901,213.31
Non-Research & Development EUR 0.00
Norway
Research & Development EUR 0.00
Non-Research & Development EUR 1,000.00
Poland
Research & Development PLN 763,625.40
Non-Research & Development PLN 0.00
Portugal
Research & Development EUR 50,611.33
Non-Research & Development EUR 0.00
Romania
Research & Development EUR 0.00
Non-Research & Development EUR 0.00
Russia
Research & Development EUR 137,576.09
Non-Research & Development EUR 0.00
Serbia
Research & Development EUR 0.00
Non-Research & Development EUR 0.00
Slovakia
Research & Development EUR 600.00
Non-Research & Development EUR 0.00
Slovenia
Research & Development EUR 0.00
Non-Research & Development EUR 0.00
Spain
Research & Development EUR 0.00
Non-Research & Development EUR 0.00
Sweden
Research & Development EUR 750.00
Non-Research & Development EUR 0.00
Switzerland
Research & Development CHF 16,709.28
Non-Research & Development CHF 98,164.00
Turkey
Research & Development EUR 0.00
Non-Research & Development EUR 0.00
Ukraine
Research & Development EUR 154,057.91
Non-Research & Development EUR 0.00
United Kingdom
Research & Development GBP 246,849.28
Non-Research & Development GBP 96,671.68

 

* The Mitsubishi Tanabe Pharma Group has established legal entities in the United Kingdom, Germany and Switzerland and therefore disclosure is made according to local requirements for these countries